{"nctId":"NCT02403674","briefTitle":"Comparison of Doravirine, Tenofovir, Lamivudine (MK-1439A) and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439A-021)","startDateStruct":{"date":"2015-06-05","type":"ACTUAL"},"conditions":["Human Immunodeficiency Virus (HIV)"],"count":734,"armGroups":[{"label":"Doravirine, Tenofovir, Lamivudine","type":"EXPERIMENTAL","interventionNames":["Drug: Doravirine, Tenofovir, Lamivudine","Drug: Placebo"]},{"label":"ATRIPLA™","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: ATRIPLA™","Drug: Placebo"]}],"interventions":[{"name":"Doravirine, Tenofovir, Lamivudine","otherNames":["MK-1439A"]},{"name":"ATRIPLA™","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Is HIV-1 positive as determined by a positive result on an enzyme-immunoassay, has screening plasma HIV-1 RNA (determined by the central laboratory) ≥1000 copies/mL within 45 days prior to the treatment phase of this study, and has HIV treatment indicated based on physician assessment\n* Has never received antiretroviral therapy (ART)\n* Is highly unlikely to either become pregnant or impregnate a partner\n\nExclusion Criteria:\n\n* Has a history or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might confound results of the study\n* Is a user of recreational or illicit drugs or has a recent history of alcohol/drug abuse\n* Has been treated for a viral infection other than HIV-1 (e.g., hepatitis B) with an agent that is active against HIV-1\n* Has participated in a study with an investigational drug/device within 30 days prior to Screening\n* Has used systemic immunosuppressive therapy or immune modulators within 30 days prior to treatment in this study or is anticipated to need them during the course of the study\n* Has a current (active) diagnosis of acute hepatitis due to any cause (note: participants with chronic hepatitis B and C may enter the study as long as they fulfill all entry criteria, have stable liver function tests, and have no significant impairment of hepatic synthetic function)\n* Is a female who is pregnant, breastfeeding, or expecting to conceive\n* Is a female and is expecting to donate eggs or is male and is expecting to donate sperm (investigators will provide appropriate guidance regarding egg and/or sperm donation after completion of the study treatment regimen)\n* Has evidence of decompensated liver disease manifested by the presence of or a history of ascites, esophageal or gastric variceal bleeding, hepatic encephalopathy or other signs or symptoms of advanced liver diseases, or has liver cirrhosis and a Child-Pugh Class C score or Pugh-Turcotte (CPT) score \\> 9","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With HIV-1 Ribonucleic Acid (RNA) <50 Copies/mL at Week 48","description":"The percentage of participants in each arm with HIV-1 RNA levels \\<50 copies/mL at Week 48 was determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) \"snapshot\" approach in which all missing data are considered treatment failures, regardless of the reason.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84.3","spread":null},{"groupId":"OG001","value":"80.8","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Tier-1 Neuropsychiatric Adverse Events (AEs)","description":"The percentage of participants in each arm experiencing ≥1 pre-specified Tier-1 neuropsychiatric AEs was determined. The list of Tier-1 neuropsychiatric AE categories included \"dizziness\", \"sleep disorders and disturbances\", and \"altered sensorium\" (including disturbance in attention).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.8","spread":null},{"groupId":"OG001","value":"37.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.1","spread":null},{"groupId":"OG001","value":"25.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":null},{"groupId":"OG001","value":"8.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 96","description":"The percentage of participants in each arm with HIV-1 RNA levels \\<50 copies/mL at Week 96 were determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. The US Food and Drug Administration (FDA) \"snapshot\" approach (i.e., all missing data handled as treatment failures, regardless of the reason) were used for efficacy analyses.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.5","spread":null},{"groupId":"OG001","value":"73.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HIV-1 RNA <40 Copies/mL at Week 48","description":"The percentage of participants in each arm with HIV-1 RNA levels \\<40 copies/mL (including target detected and target not detected) at Week 48 was determined. Plasma HIV RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) \"snapshot\" approach in which all missing data are considered treatment failures, regardless of the reason.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.8","spread":null},{"groupId":"OG001","value":"79.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HIV-1 RNA <40 Copies/mL at Week 96","description":"The percentage of participants in each arm with HIV-1 RNA levels \\<40 copies/mL (including target detected and target not detected) at Week 96 were determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. The US Food and Drug Administration (FDA) \"snapshot\" approach (i.e., all missing data handled as treatment failures, regardless of the reason) were used for efficacy analyses.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76.1","spread":null},{"groupId":"OG001","value":"72.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4 Cell Counts at Week 48","description":"The mean change from baseline in CD4 cell counts at Week 48 was assessed using the Observed Failure (OF) approach. With the OF approach, baseline values were carried forward for participants who discontinued prior to Week 48 due to lack of efficacy. Cell counts at Baseline and Week 48 were measured and expressed as cells/mm\\^3, and percent change was then calculated as \\[(Baseline counts - Week 48 counts)\\*100\\]. CD4 cell counts were quantified by a central laboratory using a commercially available assay.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"198.4","spread":null},{"groupId":"OG001","value":"188.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4 Cell Counts at Week 96","description":"The mean change from baseline in CD4 cell counts at Week 96 were assessed using the OF approach. With the OF approach, baseline values were carried forward for participants who discontinued prior to Week 96 due to lack of efficacy. Cell counts at Baseline and Week 96 were measured and expressed as cells/mm\\^3, and percent change was calculated as \\[(Baseline counts - Week 96 counts)\\*100\\]. CD4 cell counts were quantified by a central laboratory using a commercially available assay.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"237.7","spread":null},{"groupId":"OG001","value":"223.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Experiencing ≥1 AE","description":"An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.7","spread":null},{"groupId":"OG001","value":"90.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Discontinuing From Study Medication Due to an AE(s)","description":"An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":null},{"groupId":"OG001","value":"6.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Tier-2 Neuropsychiatric AEs","description":"The percentage of participants in each arm experiencing ≥1 pre-specified Tier-2 neuropsychiatric AEs was determined. The list of Tier-2 neuropsychiatric AE categories included \"depression and suicide/self-injury\" and \"psychosis and psychotic disorders\".","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":null},{"groupId":"OG001","value":"6.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":null},{"groupId":"OG001","value":"1.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting LDL-C at Week 48","description":"The mean percent change from baseline in fasting (fast duration of ≥8 hours) LDL-C levels at Week 48 was determined for each arm. The Last Observation Carry Forward (LOCF) approach was applied to missing data and data collected after a participant initiated lipid-modifying therapy.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.58","spread":null},{"groupId":"OG001","value":"8.74","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Non-HDL-C at Week 48","description":"The mean percent change from baseline in fasting (fast duration of ≥8 hours) non-HDL-C levels at Week 48 was determined for each arm. The LOCF approach was applied to missing data and data collected after a participant initiated lipid-modifying therapy.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.83","spread":null},{"groupId":"OG001","value":"13.26","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Cholesterol at Week 48","description":"The mean percent change from baseline in fasting (fast duration of ≥8 hours) cholesterol levels at Week 48 was determined for each arm. The LOCF approach was applied to missing data and data collected after a participant initiated lipid-modifying therapy.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.97","spread":null},{"groupId":"OG001","value":"21.77","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Triglycerides at Week 48","description":"The mean percent change from baseline in fasting (fast duration of ≥8 hours) triglycerides levels at Week 48 was determined for each arm. The LOCF approach was applied to missing data and data collected after a participant initiated lipid-modifying therapy.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.40","spread":null},{"groupId":"OG001","value":"22.01","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting HDL-C at Week 48","description":"The mean percent change from baseline in fasting (fast duration of ≥8 hours) HDL-C levels at Week 48 was determined for each arm. The LOCF approach was applied to missing data and data collected after a participant initiated lipid-modifying therapy.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.86","spread":null},{"groupId":"OG001","value":"8.51","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HIV-1 RNA Below the Limit of Quantification (BLoQ) at Week 48","description":"The percentage of participants in each arm with HIV-1 RNA levels BLoQ of 40 copies/mL and target not detected at Week 48 was determined. Plasma HIV RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled as observed.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.6","spread":null},{"groupId":"OG001","value":"55.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HIV-1 RNA BLoQ at Week 96","description":"The percentage of participants in each arm with HIV-1 RNA levels BLoQ of 40 copies/mL and target not detected at Week 96 was determined. Plasma HIV RNA levels was quantified with the Abbott RealTime HIV-1 Assay. Data was handled as observed.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.3","spread":null},{"groupId":"OG001","value":"59.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Plasma Concentration of Doravirine at Week 48","description":"Plasma samples were collected for analysis of doravirine concentration at Week 48. A total of 2 samples were collected: 1 prior to dosing and 1 collected between 0.5 and 2 hours post-dose.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1290","spread":"799"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2330","spread":"1230"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":22,"n":364},"commonTop":["Dizziness","Nasopharyngitis","Headache","Diarrhoea","Upper respiratory tract infection"]}}}